Regulation of human calcium-independent alpha-latro-toxin-like g protein-coupled receptor
OwnerShyam Ramakrishnaninventor
Life of this patent
Estimating the term…
Abstract
Reagents which regulate human calcium-independent alpha-latrotoxin-like G protein-coupled receptor (CIRL) and reagents which bind to human CIRL gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases associated with aberrant exocytosis in both the endocrine system and the nervous system.
Claims75
An isolated polynucleotide encoding a CIRL polypeptide and being selected from the group consisting of:
- a) a polynucleotide encoding a CIRL polypeptide comprising an amino acid sequence selected form the group consisting of:
- amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- the amino acid sequence shown in SEQ ID NO:
- 2.
- b) a polynucleotide comprising the sequence of SEQ ID NO:
- 1;
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code;
- and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d).
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:2.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:1 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and detecting the reagent-polypeptide complex.
A method of screening for agents which can modulate the activity of a human CIRL, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human CIRL.
A method of screening for agents which modulate an activity of a human CIRL, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human CIRL, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human CIRL.
A method of screening for agents which modulate an activity of a human CIRL, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO:1;
- and
- detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human CIRL.
A method of reducing activity of a human CIRL, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1, whereby the activity of a human CIRL is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2;
- and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:1;
- and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2;
- and a pharmaceutically acceptable carrier.
A method of treating a CIRL disease, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human CIRL, whereby symptoms of the CIRL disease are ameliorated.
Dependencies are inferred from the claim text.